Levomilnacipran

Levomilnacipran is used to treat depression. Levomilnacipran is in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SNRIs). It works by increasing the amount of serotonin and norepinephrine, natural substances in the brain that helps maintain mental balance.

Levomilnacipran comes as an extended-release (long-acting) capsule to take by mouth. It is usually taken once daily with or without food. Take levomilnacipran at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take levomilnacipran exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the capsules whole; do not open, chew, or crush them.

Your doctor may start you on a low dose of levomilnacipran and gradually increase your dose, not more than once every 2 days.

Levomilnacipran controls depression but does not cure it. It may take several weeks or longer before you feel the full benefit of levomilnacipran. Continue to take levomilnacipran even if you feel well. Do not stop taking levomilnacipran without talking to your doctor. Your doctor will probably decrease your dose gradually. If you suddenly stop taking levomilnacipran, you may experience withdrawal symptoms such as mood changes, agitation, irritability, dizziness, ringing in the ears, shock-like sensations, anxiety, confusion, tiredness, difficulty falling asleep or staying asleep, numbness or tingling in the arms, legs, hands, or feet, headache, increased sweating, seizures, or nausea. Tell your doctor if you experience any of these symptoms when your dose of levomilnacipran is decreased.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before taking levomilnacipran,

• tell your doctor and pharmacist if you are allergic to levomilnacipran, milnacipran, any other medications, or any of the ingredients in the capsules. Ask your pharmacist for a list of the ingredients.

• tell your doctor if you are taking a monoamine oxidase (MAO) inhibitors, including isocarboxazid (Marplan), phenelzine (Nardil), selegiline (Eldepryl, Emsam, Zelapar), and tranylcypromine (Parnate) or if you have stopped taking an MAO inhibitor within the past 2 weeks or if you are taking linezolid (Zyvox) or methylene blue. Your doctor will probably tell you not to take levomilnacipran. If you stop taking levomilnacipran, you should wait at least one week before you start to take an MAO inhibitor.

• tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: amphetamines such as amphetamine (in Adderall, in Mydayis), dextroamphetamine (Dexedrine, in Adderall), and methamphetamine (Desoxyn); anticoagulants ('blood thinners') such as warfarin (Coumadin, Jantoven); aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil, Motrin), and naproxen (Aleve, Naprosyn); buspirone; clarithromycin; diuretics ('water pills'); fentanyl (Actiq, Duragesic, Fentora, Subsys); itraconazole (Sporanox); ketoconazole; lithium (Lithobid); medications for anxiety, mental illness, pain, or seizures; medications for migraine headaches such as almotriptan, eletriptan (Relpax), frovatriptan (Frova), naratriptan (Amerge), rizatriptan (Maxalt), sumatriptan (Imitrex), and zolmitriptan (Zomig); ritonavir (Norvir, in Kaletra); selective serotonin reuptake inhibitors (SSRIs) such as citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac, in Symbyax), fluvoxamine (Luvox), paroxetine (Paxil), and sertraline (Zoloft); selective serotonin/norepinephrine reuptake inhibitors (SNRIs) such as duloxetine (Cymbalta), desvenlafaxine (Pristiq), and venlafaxine (Effexor); tramadol (Conzip, Qdola, Ultram, in Ultracet); tranquilizers; tramadol (Ultram); and tricyclic antidepressants such as amitriptyline, amoxapine, clomipramine (Anafranil), desipramine (Norpramin), doxepin (Silenor), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline, and trimipramine. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with levomilnacipran, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.

• tell your doctor what herbal products and nutritional supplements you are taking, especially St. John's wort and tryptophan.

• tell your doctor if you drink or have ever drunk large amounts of alcohol or use or have ever used street drugs or have ever overused prescription medications. Also tell your doctor if you have or have ever had high blood pressure, a stroke, urinary retention or problems urinating, bleeding problems, low salt (sodium) levels in your blood, glaucoma (increased pressure in the eye that may cause loss of sight), seizures, or kidney or heart disease.

• tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. If you become pregnant while taking levomilnacipran, call your doctor.

• avoid use of alcoholic beverages while you are taking levomilnacipran.

• you should know that levomilnacipran may make you drowsy and may affect your judgment, thinking, and movements. Do not drive a car or operate machinery until you know how this medication affects you.

• you should know that levomilnacipran may cause high blood pressure. Your blood pressure and pulse (heart rate) should be checked before starting treatment and regularly while you are receiving levomilnacipran.

• you should know that levomilnacipran may cause angle-closure glaucoma (a condition where the fluid is suddenly blocked and unable to flow out of the eye causing a quick, severe increase in eye pressure which may lead to a loss of vision). Talk to your doctor about having an eye examination before you start taking this medication. If you have nausea, eye pain, changes in vision, such as seeing colored rings around lights, and swelling or redness in or around the eye, call your doctor or get emergency medical treatment right away.

Unless your doctor tells you otherwise, continue your normal diet.

Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

• Levomilnacipran may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

  • nausea

  • constipation

  • excessive sweating

  • vomiting

  • sexual problems in males; decreased sex drive, inability to get or keep an erection, or delayed or absent ejaculation

  • sexual problems in females; decreased sex drive, or delayed orgasm or unable to have an orgasm

  • decreased appetite

• Some side effects can be serious. If you experience any of these symptoms, stop taking levomilnacipran and call your doctor immediately or get emergency medical treatment:

  • rash

  • hives

  • swelling

  • difficulty breathing or swallowing

  • hallucinations (seeing things or hearing voices that do not exist)

  • confusion

  • memory problems

  • difficulty concentrating

  • agitation, fever, sweating, confusion, fast or irregular heartbeat, severe muscle stiffness or twitching, loss of coordination, nausea, vomiting, or diarrhea

  • unsteady walking that may cause falling

  • seizures

  • fainting

  • coma (loss of consciousness for a period of time)

  • abnormal bleeding or bruising

  • difficulty urinating or unable to urinate

  • rapid, pounding, or irregular heartbeat

• Levomilnacipran may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

• If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from light, excess heat and moisture (not in the bathroom).

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

If someone swallows levomilnacipran, call your local poison control center at 1-800-222-1222. If the victim has collapsed or is not breathing, call local emergency services at 911.

Symptoms of overdose may include the following:

• extreme sleepiness

• confusion

• coma (loss of consciousness for a period of time)

• dizziness

• slowed or stopped heartbeat and breathing

Keep all appointments with your doctor and the laboratory.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug	Interaction
Repaglinide	Repaglinide The metabolism of Levomilnacipran can be decreased when combined with Repaglinide.
Montelukast	Montelukast The metabolism of Levomilnacipran can be decreased when combined with Montelukast.
Insulin Glargine (rDNA origin) Injection	Insulin Glargine (rDNA origin) Injection The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Levomilnacipran.
Delavirdine	Delavirdine The metabolism of Levomilnacipran can be decreased when combined with Delavirdine.
Nevirapine	Nevirapine The metabolism of Levomilnacipran can be decreased when combined with Nevirapine.
Atorvastatin	Atorvastatin The metabolism of Levomilnacipran can be decreased when combined with Atorvastatin.
Dolasetron	Dolasetron The risk or severity of adverse effects can be increased when Dolasetron is combined with Levomilnacipran.
Anagrelide	Anagrelide The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Anagrelide.
Candesartan	Candesartan The metabolism of Levomilnacipran can be decreased when combined with Candesartan.
Cilostazol	Cilostazol Levomilnacipran may increase the antiplatelet activities of Cilostazol.
Clopidogrel	Clopidogrel The metabolism of Levomilnacipran can be decreased when combined with Clopidogrel.
Diphenoxylate	Diphenoxylate The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Levomilnacipran.
Estrogen and Progestin (Oral Contraceptives)	Estrogen and Progestin (Oral Contraceptives) Conjugated estrogens may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Fenofibrate	Fenofibrate Fenofibrate may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Guanfacine	Guanfacine The risk or severity of adverse effects can be increased when Guanfacine is combined with Levomilnacipran.
Magnesium Hydroxide	Magnesium Hydroxide Levomilnacipran may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Miglitol	Miglitol The risk or severity of hypoglycemia can be increased when Miglitol is combined with Levomilnacipran.
Mycophenolate	Mycophenolate Mycophenolic acid may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Naratriptan	Naratriptan The risk or severity of adverse effects can be increased when Naratriptan is combined with Levomilnacipran.
Olsalazine	Olsalazine The risk or severity of gastrointestinal bleeding can be increased when Olsalazine is combined with Levomilnacipran.
Paregoric	Paregoric The risk or severity of serotonin syndrome can be increased when Morphine is combined with Levomilnacipran.
Penbutolol	Penbutolol The serum concentration of Acebutolol can be increased when it is combined with Levomilnacipran.
Pentazocine	Pentazocine The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Levomilnacipran.
Potassium	Potassium Potassium cation may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.
Prednisone	Prednisone Prednisone may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Ranitidine	Ranitidine The metabolism of Levomilnacipran can be decreased when combined with Ranitidine.
Reserpine	Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Levomilnacipran.
Rizatriptan	Rizatriptan The risk or severity of adverse effects can be increased when Rizatriptan is combined with Levomilnacipran.
Sumatriptan	Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with Levomilnacipran.
Tacrolimus	Tacrolimus Tacrolimus may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Tizanidine	Tizanidine The risk or severity of adverse effects can be increased when Tizanidine is combined with Levomilnacipran.
Triamcinolone	Triamcinolone The metabolism of Levomilnacipran can be increased when combined with Triamcinolone.
Zolmitriptan	Zolmitriptan The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Levomilnacipran.
Ampicillin Injection	Ampicillin Injection Ampicillin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Doxycycline Injection	Doxycycline Injection Doxycycline may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Fluconazole Injection	Fluconazole Injection Fluconazole may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Foscarnet Injection	Foscarnet Injection Foscarnet may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Hydromorphone Injection	Hydromorphone Injection The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Levomilnacipran.
Levofloxacin Injection	Levofloxacin Injection Levofloxacin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Meperidine Injection	Meperidine Injection The risk or severity of serotonin syndrome can be increased when Meperidine is combined with Levomilnacipran.
Methylprednisolone Injection	Methylprednisolone Injection The metabolism of Levomilnacipran can be increased when combined with Methylprednisolone.
Metoclopramide Injection	Metoclopramide Injection The risk or severity of adverse effects can be increased when Metoclopramide is combined with Levomilnacipran.
Metronidazole Injection	Metronidazole Injection The metabolism of Levomilnacipran can be decreased when combined with Metronidazole.
Morphine Injection	Morphine Injection The risk or severity of serotonin syndrome can be increased when Morphine is combined with Levomilnacipran.
Pamidronate Injection	Pamidronate Injection Pamidronic acid may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Vancomycin Injection	Vancomycin Injection Levomilnacipran may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Zidovudine Injection	Zidovudine Injection The metabolism of Levomilnacipran can be decreased when combined with Zidovudine.
Altretamine	Altretamine Amphetamine may increase the serotonergic activities of Levomilnacipran.
Cefuroxime	Cefuroxime Cefuroxime may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Cyclosporine	Cyclosporine The metabolism of Levomilnacipran can be decreased when combined with Cyclosporine.
Ondansetron	Ondansetron The risk or severity of adverse effects can be increased when Ondansetron is combined with Levomilnacipran.
Enoxaparin Injection	Enoxaparin Injection The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Enoxaparin.
Granisetron	Granisetron The risk or severity of adverse effects can be increased when Granisetron is combined with Levomilnacipran.
Torsemide	Torsemide The metabolism of Levomilnacipran can be decreased when combined with Torasemide.
Olanzapine	Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Levomilnacipran.
Alosetron	Alosetron The risk or severity of adverse effects can be increased when Alosetron is combined with Levomilnacipran.
Entacapone	Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Levomilnacipran.
Hydroxychloroquine	Hydroxychloroquine The metabolism of Levomilnacipran can be decreased when combined with Hydroxychloroquine.
Meloxicam	Meloxicam The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Meloxicam.
Orlistat	Orlistat The metabolism of Levomilnacipran can be increased when combined with Orlistat.
Oxcarbazepine	Oxcarbazepine The metabolism of Levomilnacipran can be increased when combined with Oxcarbazepine.
Pantoprazole	Pantoprazole Pantoprazole may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Temozolomide	Temozolomide Temozolomide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Zaleplon	Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Levomilnacipran.
Anakinra	Anakinra The metabolism of Levomilnacipran can be increased when combined with Anakinra.
Desloratadine	Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Levomilnacipran.
Linezolid	Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Levomilnacipran.
Pentosan Polysulfate	Pentosan Polysulfate The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Pentosan polysulfate.
Trimipramine	Trimipramine The metabolism of Levomilnacipran can be decreased when combined with Trimipramine.
Etanercept Injection	Etanercept Injection The metabolism of Levomilnacipran can be increased when combined with Etanercept.
Glycopyrrolate	Glycopyrrolate Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.
Modafinil	Modafinil The metabolism of Levomilnacipran can be increased when combined with Modafinil.
Perindopril	Perindopril Perindopril may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Tenofovir	Tenofovir Tenofovir may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Choline Magnesium Trisalicylate	Choline Magnesium Trisalicylate The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Choline magnesium trisalicylate.
Epinephrine Injection	Epinephrine Injection Levomilnacipran may increase the tachycardic activities of Epinephrine.
Eplerenone	Eplerenone Eplerenone may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.
Escitalopram	Escitalopram The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Levomilnacipran.
Zonisamide	Zonisamide The risk or severity of adverse effects can be increased when Zonisamide is combined with Levomilnacipran.
Adalimumab Injection	Adalimumab Injection The metabolism of Levomilnacipran can be increased when combined with Adalimumab.
Aripiprazole	Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Levomilnacipran.
Atomoxetine	Atomoxetine The risk or severity of adverse effects can be increased when Atomoxetine is combined with Levomilnacipran.
Dexmethylphenidate	Dexmethylphenidate The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Levomilnacipran.
Teriparatide Injection	Teriparatide Injection The therapeutic efficacy of Teriparatide can be decreased when used in combination with Levomilnacipran.
Atazanavir	Atazanavir The metabolism of Levomilnacipran can be decreased when combined with Atazanavir.
Almotriptan	Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with Levomilnacipran.
Eletriptan	Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Levomilnacipran.
Mefloquine	Mefloquine The metabolism of Levomilnacipran can be decreased when combined with Mefloquine.
Emtricitabine	Emtricitabine Emtricitabine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Memantine	Memantine Memantine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Tegaserod	Tegaserod The metabolism of Levomilnacipran can be decreased when combined with Tegaserod.
Tadalafil	Tadalafil Tadalafil may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Frovatriptan	Frovatriptan The risk or severity of adverse effects can be increased when Frovatriptan is combined with Levomilnacipran.
Progesterone	Progesterone The metabolism of Levomilnacipran can be increased when combined with Progesterone.
Apomorphine Injection	Apomorphine Injection The risk or severity of adverse effects can be increased when Apomorphine is combined with Levomilnacipran.
Infliximab Injection	Infliximab Injection The metabolism of Levomilnacipran can be increased when combined with Infliximab.
Protriptyline	Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Levomilnacipran.
Rifaximin	Rifaximin The metabolism of Levomilnacipran can be increased when combined with Rifaximin.
Duloxetine	Duloxetine The metabolism of Levomilnacipran can be decreased when combined with Duloxetine.
Tinidazole	Tinidazole Tinidazole may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Trospium	Trospium Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Trospium.
Bosentan	Bosentan The metabolism of Levomilnacipran can be increased when combined with Bosentan.
Cefditoren	Cefditoren Cefdinir may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Cinacalcet	Cinacalcet The metabolism of Levomilnacipran can be decreased when combined with Cinacalcet.
Cyanocobalamin Injection	Cyanocobalamin Injection Hydroxocobalamin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Erlotinib	Erlotinib The metabolism of Levomilnacipran can be decreased when combined with Erlotinib.
Eszopiclone	Eszopiclone The risk or severity of CNS depression can be increased when Levomilnacipran is combined with Eszopiclone.
Ganciclovir	Ganciclovir Ganciclovir may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Insulin Aspart (rDNA Origin) Injection	Insulin Aspart (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Insulin aspart is combined with Levomilnacipran.
Ribavirin	Ribavirin Ribavirin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Solifenacin	Solifenacin Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.
Valganciclovir	Valganciclovir Valganciclovir may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Voriconazole	Voriconazole The metabolism of Levomilnacipran can be decreased when combined with Voriconazole.
Adefovir	Adefovir Adefovir may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Dextroamphetamine	Dextroamphetamine Amphetamine may increase the serotonergic activities of Levomilnacipran.
Peginterferon Alfa-2b (PEG-Intron)	Peginterferon Alfa-2b (PEG-Intron) The metabolism of Levomilnacipran can be decreased when combined with Peginterferon alfa-2b.
Pramlintide Injection	Pramlintide Injection The risk or severity of hypoglycemia can be increased when Pramlintide is combined with Levomilnacipran.
Sodium Oxybate	Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.
Exenatide Injection	Exenatide Injection The risk or severity of hypoglycemia can be increased when Exenatide is combined with Levomilnacipran.
Isocarboxazid	Isocarboxazid Isocarboxazid may increase the serotonergic activities of Levomilnacipran.
Ramelteon	Ramelteon The risk or severity of adverse effects can be increased when Ramelteon is combined with Levomilnacipran.
Darifenacin	Darifenacin The metabolism of Darifenacin can be decreased when combined with Levomilnacipran.
Fentanyl	Fentanyl The risk or severity of serotonin syndrome can be increased when Levomilnacipran is combined with Fentanyl.
Pregabalin	Pregabalin The therapeutic efficacy of Levomilnacipran can be increased when used in combination with Pregabalin.
Deferasirox	Deferasirox The metabolism of Levomilnacipran can be increased when combined with Deferasirox.
Phenylephrine	Phenylephrine Levomilnacipran may increase the tachycardic activities of Phenylephrine.
Tipranavir	Tipranavir The metabolism of Tipranavir can be decreased when combined with Levomilnacipran.
Felbamate	Felbamate The metabolism of Levomilnacipran can be increased when combined with Felbamate.
Insulin Detemir (rDNA Origin) Injection	Insulin Detemir (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Insulin detemir is combined with Levomilnacipran.
Ranolazine	Ranolazine The serum concentration of Levomilnacipran can be increased when it is combined with Ranolazine.
Abatacept Injection	Abatacept Injection The metabolism of Levomilnacipran can be increased when combined with Abatacept.
Rasagiline	Rasagiline Rasagiline may increase the serotonergic activities of Levomilnacipran.
Imatinib	Imatinib The metabolism of Levomilnacipran can be decreased when combined with Imatinib.
Sitagliptin	Sitagliptin The metabolism of Levomilnacipran can be decreased when combined with Sitagliptin.
Varenicline	Varenicline Varenicline may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Gefitinib	Gefitinib The metabolism of Levomilnacipran can be decreased when combined with Gefitinib.
Albuterol	Albuterol Levomilnacipran may increase the tachycardic activities of Salbutamol.
Paliperidone	Paliperidone The risk or severity of adverse effects can be increased when Paliperidone is combined with Levomilnacipran.
Bortezomib	Bortezomib The metabolism of Levomilnacipran can be decreased when combined with Bortezomib.
Clofarabine Injection	Clofarabine Injection Clofarabine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Insulin Glulisine (rDNA origin) Injection	Insulin Glulisine (rDNA origin) Injection The risk or severity of hypoglycemia can be increased when Insulin glulisine is combined with Levomilnacipran.
Lubiprostone	Lubiprostone Lubiprostone may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Posaconazole	Posaconazole The metabolism of Levomilnacipran can be decreased when combined with Posaconazole.
Primaquine	Primaquine The metabolism of Levomilnacipran can be decreased when combined with Primaquine.
Darunavir	Darunavir The metabolism of Darunavir can be decreased when combined with Levomilnacipran.
Pemetrexed Injection	Pemetrexed Injection Levomilnacipran may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Dimenhydrinate	Dimenhydrinate The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Levomilnacipran.
Lisdexamfetamine	Lisdexamfetamine The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Levomilnacipran.
Nabilone	Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.
Sorafenib	Sorafenib The metabolism of Levomilnacipran can be decreased when combined with Sorafenib.
Sunitinib	Sunitinib The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Sunitinib.
Dronabinol	Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.
Lapatinib	Lapatinib The metabolism of Levomilnacipran can be decreased when combined with Lapatinib.
Levocetirizine	Levocetirizine The risk or severity of adverse effects can be increased when Levocetirizine is combined with Levomilnacipran.
Pegaptanib Injection	Pegaptanib Injection Pegaptanib may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Mexiletine	Mexiletine The metabolism of Levomilnacipran can be decreased when combined with Mexiletine.
Armodafinil	Armodafinil The metabolism of Levomilnacipran can be increased when combined with Armodafinil.
Azacitidine Injection	Azacitidine Injection Azacitidine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Temsirolimus	Temsirolimus The metabolism of Levomilnacipran can be decreased when combined with Temsirolimus.
Lenalidomide	Lenalidomide Lenalidomide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Nilotinib	Nilotinib The metabolism of Levomilnacipran can be decreased when combined with Nilotinib.
Bexarotene	Bexarotene The metabolism of Levomilnacipran can be increased when combined with Bexarotene.
Budesonide	Budesonide The metabolism of Levomilnacipran can be increased when combined with Budesonide.
Desmopressin	Desmopressin The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Desmopressin.
OnabotulinumtoxinA Injection	OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Levomilnacipran.
RimabotulinumtoxinB Injection	RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Levomilnacipran.
Doripenem Injection	Doripenem Injection Doripenem may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Etravirine	Etravirine The metabolism of Levomilnacipran can be increased when combined with Etravirine.
Arsenic Trioxide Injection	Arsenic Trioxide Injection Arsenic trioxide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Desvenlafaxine	Desvenlafaxine The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Levomilnacipran.
Cevimeline	Cevimeline Cevimeline may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Nebivolol	Nebivolol The serum concentration of Nebivolol can be increased when it is combined with Levomilnacipran.
Tretinoin	Tretinoin The metabolism of Levomilnacipran can be decreased when combined with Tretinoin.
Flecainide	Flecainide The metabolism of Flecainide can be decreased when combined with Levomilnacipran.
Certolizumab Injection	Certolizumab Injection The metabolism of Levomilnacipran can be increased when combined with Certolizumab pegol.
Daptomycin Injection	Daptomycin Injection Daptomycin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Mitotane	Mitotane The metabolism of Levomilnacipran can be increased when combined with Mitotane.
Methylnaltrexone Injection	Methylnaltrexone Injection Methylnaltrexone may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Rufinamide	Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Levomilnacipran.
Midazolam	Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Levomilnacipran.
Naltrexone Injection	Naltrexone Injection The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Levomilnacipran.
Dexrazoxane Injection	Dexrazoxane Injection Dexrazoxane may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Eltrombopag	Eltrombopag The metabolism of Levomilnacipran can be decreased when combined with Eltrombopag.
Milnacipran	Milnacipran The risk or severity of adverse effects can be increased when Milnacipran is combined with Levomilnacipran.
Plerixafor Injection	Plerixafor Injection Plerixafor may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Fesoterodine	Fesoterodine Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
Betaxolol	Betaxolol The serum concentration of Betaxolol can be increased when it is combined with Levomilnacipran.
Iloperidone	Iloperidone The risk or severity of adverse effects can be increased when Iloperidone is combined with Levomilnacipran.
Prasugrel	Prasugrel The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Prasugrel.
Lacosamide	Lacosamide The risk or severity of adverse effects can be increased when Lacosamide is combined with Levomilnacipran.
Everolimus	Everolimus The metabolism of Everolimus can be decreased when combined with Levomilnacipran.
Tolvaptan (low blood sodium)	Tolvaptan (low blood sodium) Tolvaptan may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.
Dronedarone	Dronedarone The metabolism of Dronedarone can be decreased when combined with Levomilnacipran.
AbobotulinumtoxinA Injection	AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Levomilnacipran.
Pralatrexate Injection	Pralatrexate Injection Pralatrexate may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Palonosetron Injection	Palonosetron Injection The risk or severity of adverse effects can be increased when Palonosetron is combined with Levomilnacipran.
Saxagliptin	Saxagliptin The risk or severity of hypoglycemia can be increased when Saxagliptin is combined with Levomilnacipran.
Telavancin Injection	Telavancin Injection Telavancin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Tapentadol	Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.
Topotecan	Topotecan The metabolism of Levomilnacipran can be increased when combined with Topotecan.
Golimumab Injection	Golimumab Injection The metabolism of Levomilnacipran can be increased when combined with Golimumab.
Pazopanib	Pazopanib The metabolism of Levomilnacipran can be decreased when combined with Pazopanib.
Asenapine	Asenapine The risk or severity of adverse effects can be increased when Asenapine is combined with Levomilnacipran.
Vigabatrin	Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Levomilnacipran.
Pitavastatin	Pitavastatin The metabolism of Levomilnacipran can be decreased when combined with Pitavastatin.
Oxymorphone	Oxymorphone The risk or severity of serotonin syndrome can be increased when Oxymorphone is combined with Levomilnacipran.
Dabigatran	Dabigatran The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Dabigatran.
Liraglutide Injection	Liraglutide Injection The risk or severity of hypoglycemia can be increased when Liraglutide is combined with Levomilnacipran.
Tocilizumab Injection	Tocilizumab Injection The metabolism of Levomilnacipran can be increased when combined with Tocilizumab.
Dalfampridine	Dalfampridine Dalfampridine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
IncobotulinumtoxinA Injection	IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Levomilnacipran.
Cabazitaxel Injection	Cabazitaxel Injection The metabolism of Levomilnacipran can be decreased when combined with Cabazitaxel.
Ceftaroline Injection	Ceftaroline Injection Ceftaroline fosamil may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Lurasidone	Lurasidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Levomilnacipran.
Acetaminophen Injection	Acetaminophen Injection The metabolism of Levomilnacipran can be increased when combined with Acetaminophen.
Vilazodone	Vilazodone The metabolism of Levomilnacipran can be decreased when combined with Vilazodone.
Ipilimumab Injection	Ipilimumab Injection Ipilimumab may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Denileukin Diftitox Injection	Denileukin Diftitox Injection Aldesleukin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Terbutaline Injection	Terbutaline Injection Levomilnacipran may increase the tachycardic activities of Terbutaline.
Roflumilast	Roflumilast Roflumilast may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Linagliptin	Linagliptin The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Linagliptin.
Rilpivirine	Rilpivirine The metabolism of Rilpivirine can be decreased when combined with Levomilnacipran.
Potassium Iodide	Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Levomilnacipran.
Cyclophosphamide Injection	Cyclophosphamide Injection The metabolism of Levomilnacipran can be increased when combined with Cyclophosphamide.
Abiraterone	Abiraterone The metabolism of Levomilnacipran can be decreased when combined with Abiraterone.
Rivaroxaban	Rivaroxaban The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Rivaroxaban.
Ticagrelor	Ticagrelor The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Ticagrelor.
Ruxolitinib	Ruxolitinib Ruxolitinib may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Clobazam	Clobazam The metabolism of Levomilnacipran can be decreased when combined with Clobazam.
Vemurafenib	Vemurafenib The metabolism of Levomilnacipran can be increased when combined with Vemurafenib.
Vismodegib	Vismodegib The metabolism of Levomilnacipran can be decreased when combined with Vismodegib.
Deferiprone	Deferiprone Deferiprone may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Cabergoline	Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Levomilnacipran.
Naloxone Injection	Naloxone Injection The metabolism of Levomilnacipran can be decreased when combined with Naloxone.
Fondaparinux Injection	Fondaparinux Injection The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Fondaparinux.
Ezogabine	Ezogabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Levomilnacipran.
Iloprost	Iloprost The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Iloprost.
Enzalutamide	Enzalutamide The metabolism of Levomilnacipran can be increased when combined with Enzalutamide.
Mirabegron	Mirabegron The metabolism of Levomilnacipran can be decreased when combined with Mirabegron.
Regorafenib	Regorafenib The metabolism of Levomilnacipran can be decreased when combined with Regorafenib.
Bosutinib	Bosutinib The metabolism of Levomilnacipran can be decreased when combined with Bosutinib.
Corticotropin, Repository Injection	Corticotropin, Repository Injection The metabolism of Levomilnacipran can be increased when combined with Corticotropin.
Teriflunomide	Teriflunomide The metabolism of Levomilnacipran can be decreased when combined with Teriflunomide.
Lorcaserin	Lorcaserin The risk or severity of hypoglycemia can be increased when Mecasermin is combined with Levomilnacipran.
Cabozantinib (thyroid cancer)	Cabozantinib (thyroid cancer) The metabolism of Levomilnacipran can be decreased when combined with Cabozantinib.
Teduglutide Injection	Teduglutide Injection Teduglutide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Icosapent Ethyl	Icosapent Ethyl Levomilnacipran may increase the antiplatelet activities of Icosapent ethyl.
Alogliptin	Alogliptin The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Levomilnacipran.
Ponatinib	Ponatinib The metabolism of Levomilnacipran can be decreased when combined with Ponatinib.
Pomalidomide	Pomalidomide The risk or severity of adverse effects can be increased when Pomalidomide is combined with Levomilnacipran.
Apixaban	Apixaban The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Apixaban.
Canagliflozin	Canagliflozin The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Canagliflozin.
Methazolamide	Methazolamide Methazolamide may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.
Dabrafenib	Dabrafenib The metabolism of Levomilnacipran can be increased when combined with Dabrafenib.
Ospemifene	Ospemifene The metabolism of Levomilnacipran can be decreased when combined with Ospemifene.
Trametinib	Trametinib The metabolism of Levomilnacipran can be increased when combined with Trametinib.
Ertapenem Injection	Ertapenem Injection Ertapenem may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Vortioxetine	Vortioxetine The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Vortioxetine.
Perampanel	Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.
Ibrutinib	Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Levomilnacipran.
Ketorolac Injection	Ketorolac Injection The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Ketorolac.
Sofosbuvir	Sofosbuvir Levomilnacipran may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Dapagliflozin	Dapagliflozin The risk or severity of hypoglycemia can be increased when Dapagliflozin is combined with Levomilnacipran.
Apremilast	Apremilast The metabolism of Levomilnacipran can be increased when combined with Apremilast.
Droxidopa	Droxidopa Levomilnacipran may increase the tachycardic activities of Droxidopa.
Siltuximab Injection	Siltuximab Injection The metabolism of Levomilnacipran can be increased when combined with Siltuximab.
Albiglutide Injection	Albiglutide Injection The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Albiglutide.
Eslicarbazepine	Eslicarbazepine The metabolism of Levomilnacipran can be increased when combined with Eslicarbazepine.
Testosterone Injection	Testosterone Injection The metabolism of Levomilnacipran can be increased when combined with Testosterone.
Oritavancin Injection	Oritavancin Injection The metabolism of Levomilnacipran can be increased when combined with Oritavancin.
Empagliflozin	Empagliflozin The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Empagliflozin.
Vorapaxar	Vorapaxar The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Vorapaxar.
Hydrocodone	Hydrocodone Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.
Suvorexant	Suvorexant Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Dulaglutide Injection	Dulaglutide Injection The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Dulaglutide.
Edoxaban	Edoxaban The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Edoxaban.
Methamphetamine	Methamphetamine The risk or severity of adverse effects can be increased when Metamfetamine is combined with Levomilnacipran.
Tasimelteon	Tasimelteon The risk or severity of adverse effects can be increased when Tasimelteon is combined with Levomilnacipran.
Riociguat	Riociguat The metabolism of Riociguat can be decreased when combined with Levomilnacipran.
Lanreotide Injection	Lanreotide Injection The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Levomilnacipran.
Secukinumab Injection	Secukinumab Injection The metabolism of Levomilnacipran can be increased when combined with Secukinumab.
Risperidone Injection	Risperidone Injection The risk or severity of adverse effects can be increased when Risperidone is combined with Levomilnacipran.
Insulin Human Inhalation	Insulin Human Inhalation The risk or severity of hypoglycemia can be increased when Insulin human is combined with Levomilnacipran.
Lenvatinib	Lenvatinib The metabolism of Levomilnacipran can be increased when combined with Lenvatinib.
Naloxegol	Naloxegol The metabolism of Levomilnacipran can be decreased when combined with Naloxegol.
Panobinostat	Panobinostat The metabolism of Levomilnacipran can be decreased when combined with Panobinostat.
Haloperidol Injection	Haloperidol Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Levomilnacipran.
Amiloride	Amiloride Amiloride may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.
Isavuconazonium Injection	Isavuconazonium Injection The metabolism of Levomilnacipran can be increased when combined with Isavuconazonium.
Macitentan	Macitentan Levomilnacipran may decrease the excretion rate of Macitentan which could result in a higher serum level.
Flibanserin	Flibanserin The risk or severity of adverse effects can be increased when Flibanserin is combined with Levomilnacipran.
Rolapitant	Rolapitant The metabolism of Levomilnacipran can be decreased when combined with Rolapitant.
Prednisolone	Prednisolone The metabolism of Levomilnacipran can be increased when combined with Prednisolone.
Brexpiprazole	Brexpiprazole The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Levomilnacipran.
Ziprasidone Injection	Ziprasidone Injection The risk or severity of adverse effects can be increased when Ziprasidone is combined with Levomilnacipran.
Cariprazine	Cariprazine The risk or severity of adverse effects can be increased when Cariprazine is combined with Levomilnacipran.
Penicillin G Procaine Injection	Penicillin G Procaine Injection Levomilnacipran may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Eluxadoline	Eluxadoline The risk or severity of serotonin syndrome can be increased when Levomilnacipran is combined with Eluxadoline.
Insulin Degludec (rDNA Origin) Injection	Insulin Degludec (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Insulin degludec.
Trabectedin Injection	Trabectedin Injection The metabolism of Levomilnacipran can be decreased when combined with Trabectedin.
Osimertinib	Osimertinib The metabolism of Levomilnacipran can be increased when combined with Osimertinib.
Ixazomib	Ixazomib Levomilnacipran may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Rifapentine	Rifapentine The metabolism of Levomilnacipran can be increased when combined with Rifapentine.
Lesinurad	Lesinurad Levomilnacipran may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Amphotericin B Liposomal Injection	Amphotericin B Liposomal Injection Amphotericin B may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Dexamethasone Injection	Dexamethasone Injection The metabolism of Levomilnacipran can be increased when combined with Dexamethasone.
Defibrotide Injection	Defibrotide Injection The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Defibrotide.
Brivaracetam Injection	Brivaracetam Injection The risk or severity of adverse effects can be increased when Brivaracetam is combined with Levomilnacipran.
Cobicistat	Cobicistat The metabolism of Levomilnacipran can be decreased when combined with Cobicistat.
Midodrine	Midodrine Levomilnacipran may increase the tachycardic activities of Midodrine.
Selexipag	Selexipag The metabolism of Selexipag can be decreased when combined with Levomilnacipran.
Pimavanserin	Pimavanserin The risk or severity of adverse effects can be increased when Pimavanserin is combined with Levomilnacipran.
Diphenhydramine Injection	Diphenhydramine Injection The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Levomilnacipran.
Furosemide Injection	Furosemide Injection Furosemide may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.
Rucaparib	Rucaparib The metabolism of Levomilnacipran can be decreased when combined with Rucaparib.
Lixisenatide Injection	Lixisenatide Injection The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Lixisenatide.
Ribociclib	Ribociclib The metabolism of Levomilnacipran can be decreased when combined with Ribociclib.
Parathyroid Hormone Injection	Parathyroid Hormone Injection The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Levomilnacipran.
Brigatinib	Brigatinib The metabolism of Levomilnacipran can be increased when combined with Brigatinib.
Doxepin (Insomnia)	Doxepin (Insomnia) The risk or severity of adverse effects can be increased when Doxepin is combined with Levomilnacipran.
Deutetrabenazine	Deutetrabenazine Levomilnacipran may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
Valbenazine	Valbenazine Levomilnacipran may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Safinamide	Safinamide Safinamide may increase the serotonergic activities of Levomilnacipran.
Naldemedine	Naldemedine Levomilnacipran may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Sarilumab Injection	Sarilumab Injection The metabolism of Levomilnacipran can be increased when combined with Sarilumab.
Midostaurin	Midostaurin The metabolism of Levomilnacipran can be decreased when combined with Midostaurin.
Abaloparatide Injection	Abaloparatide Injection The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Levomilnacipran.
Enasidenib	Enasidenib The metabolism of Levomilnacipran can be increased when combined with Enasidenib.
Aprepitant/Fosaprepitant Injection	Aprepitant/Fosaprepitant Injection The metabolism of Levomilnacipran can be increased when combined with Fosaprepitant.
Benznidazole	Benznidazole Levomilnacipran may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Delafloxacin	Delafloxacin The metabolism of Levomilnacipran can be increased when combined with Delafloxacin.
Betrixaban	Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Levomilnacipran.
Letermovir	Letermovir The metabolism of Levomilnacipran can be decreased when combined with Letermovir.
Semaglutide Injection	Semaglutide Injection The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Semaglutide.
Tetrabenazine	Tetrabenazine The metabolism of Levomilnacipran can be decreased when combined with Tetrabenazine.
Ertugliflozin	Ertugliflozin The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Ertugliflozin.
Buprenorphine Injection	Buprenorphine Injection Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Apalutamide	Apalutamide The metabolism of Apalutamide can be increased when combined with Levomilnacipran.
Avatrombopag	Avatrombopag The metabolism of Levomilnacipran can be increased when combined with Avatrombopag.
Baricitinib	Baricitinib Levomilnacipran may decrease the excretion rate of Baricitinib which could result in a higher serum level.
Lofexidine	Lofexidine The therapeutic efficacy of Levomilnacipran can be increased when used in combination with Lofexidine.
Plazomicin Injection	Plazomicin Injection Levomilnacipran may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Eliglustat	Eliglustat The metabolism of Levomilnacipran can be decreased when combined with Eliglustat.
Encorafenib	Encorafenib The metabolism of Encorafenib can be decreased when combined with Levomilnacipran.
Ivosidenib	Ivosidenib The metabolism of Levomilnacipran can be increased when combined with Ivosidenib.
Elagolix	Elagolix The metabolism of Elagolix can be decreased when combined with Levomilnacipran.
Tafenoquine	Tafenoquine The metabolism of Levomilnacipran can be decreased when combined with Tafenoquine.
Cannabidiol	Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Levomilnacipran.
Dacomitinib	Dacomitinib The metabolism of Levomilnacipran can be decreased when combined with Dacomitinib.
Stiripentol	Stiripentol The metabolism of Levomilnacipran can be decreased when combined with Stiripentol.
Gilteritinib	Gilteritinib The therapeutic efficacy of Levomilnacipran can be decreased when used in combination with Gilteritinib.
Glasdegib	Glasdegib The metabolism of Glasdegib can be decreased when combined with Levomilnacipran.
Lorlatinib	Lorlatinib The metabolism of Lorlatinib can be increased when combined with Levomilnacipran.
Paclitaxel (with albumin) Injection	Paclitaxel (with albumin) Injection The metabolism of Levomilnacipran can be increased when combined with Paclitaxel.
Rifamycin	Rifamycin The metabolism of Levomilnacipran can be increased when combined with Rifamycin.
Prucalopride	Prucalopride Prucalopride may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Emapalumab-lzsg Injection	Emapalumab-lzsg Injection The metabolism of Levomilnacipran can be increased when combined with Emapalumab.
Acyclovir Ophthalmic	Acyclovir Ophthalmic Acyclovir may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Caplacizumab-yhdp Injection	Caplacizumab-yhdp Injection The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Caplacizumab.
Alpelisib	Alpelisib The metabolism of Levomilnacipran can be increased when combined with Alpelisib.
Brexanolone Injection	Brexanolone Injection The risk or severity of adverse effects can be increased when Brexanolone is combined with Levomilnacipran.
Solriamfetol	Solriamfetol The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Levomilnacipran.
Triclabendazole	Triclabendazole The metabolism of Levomilnacipran can be decreased when combined with Triclabendazole.
Istradefylline	Istradefylline The metabolism of Istradefylline can be decreased when combined with Levomilnacipran.
Pitolisant	Pitolisant The serum concentration of Levomilnacipran can be decreased when it is combined with Pitolisant.
Fedratinib	Fedratinib The metabolism of Levomilnacipran can be decreased when combined with Fedratinib.
Phenytoin Injection	Phenytoin Injection The metabolism of Phenytoin can be increased when combined with Levomilnacipran.
Fosphenytoin Injection	Fosphenytoin Injection The metabolism of Levomilnacipran can be increased when combined with Fosphenytoin.
Lumateperone	Lumateperone The risk or severity of adverse effects can be increased when Lumateperone is combined with Levomilnacipran.
Lasmiditan	Lasmiditan The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Levomilnacipran.
Cenobamate	Cenobamate The serum concentration of Levomilnacipran can be decreased when it is combined with Cenobamate.
Ozanimod	Ozanimod The metabolism of Ozanimod can be decreased when combined with Levomilnacipran.
Selumetinib	Selumetinib The metabolism of Selumetinib can be decreased when combined with Levomilnacipran.
Tucatinib	Tucatinib The metabolism of Tucatinib can be decreased when combined with Levomilnacipran.
Selpercatinib	Selpercatinib The serum concentration of Levomilnacipran can be increased when it is combined with Selpercatinib.
Lemborexant	Lemborexant The risk or severity of adverse effects can be increased when Lemborexant is combined with Levomilnacipran.
Fenfluramine	Fenfluramine The risk or severity of serotonin syndrome can be increased when Fenfluramine is combined with Levomilnacipran.
Octreotide	Octreotide The risk or severity of hypoglycemia can be increased when Octreotide is combined with Levomilnacipran.
Pralsetinib	Pralsetinib The metabolism of Levomilnacipran can be increased when combined with Pralsetinib.
Opicapone	Opicapone The metabolism of Levomilnacipran can be decreased when combined with Opicapone.
Satralizumab-mwge Injection	Satralizumab-mwge Injection The serum concentration of Levomilnacipran can be decreased when it is combined with Satralizumab.
Progestin-Only (drospirenone) Oral Contraceptives	Progestin-Only (drospirenone) Oral Contraceptives Drospirenone may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.
Viloxazine	Viloxazine The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Viloxazine.
Vitamin E (Alpha-Tocopherol)	Vitamin E (Alpha-Tocopherol) The metabolism of Levomilnacipran can be increased when combined with Vitamin E.
Tobramycin Injection	Tobramycin Injection Tobramycin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Theophylline	Theophylline The metabolism of Levomilnacipran can be decreased when combined with Theophylline.
Fenoprofen	Fenoprofen The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Fenoprofen.
Indomethacin	Indomethacin The risk or severity of gastrointestinal bleeding can be increased when Indomethacin is combined with Levomilnacipran.
Mefenamic Acid	Mefenamic Acid The risk or severity of gastrointestinal bleeding can be increased when Mefenamic acid is combined with Levomilnacipran.
Naproxen	Naproxen The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Naproxen.
Tolmetin	Tolmetin The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Tolmetin.
Sulindac	Sulindac The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Sulindac.
Trazodone	Trazodone The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Levomilnacipran.
Isotretinoin	Isotretinoin Isotretinoin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Sucralfate	Sucralfate Sucralfate may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Hydroxyurea	Hydroxyurea The metabolism of Levomilnacipran can be decreased when combined with Hydroxyurea.
Floxuridine	Floxuridine Floxuridine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Phenobarbital	Phenobarbital The metabolism of Levomilnacipran can be increased when combined with Phenobarbital.
Metaxalone	Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Levomilnacipran.
Methotrexate Injection	Methotrexate Injection Methotrexate may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Levorphanol	Levorphanol The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Levomilnacipran.
Primidone	Primidone The metabolism of Levomilnacipran can be increased when combined with Primidone.
Methsuximide	Methsuximide The risk or severity of adverse effects can be increased when Methsuximide is combined with Levomilnacipran.
Diethylpropion	Diethylpropion The risk or severity of adverse effects can be increased when Diethylpropion is combined with Levomilnacipran.
Chlorpromazine	Chlorpromazine The metabolism of Levomilnacipran can be decreased when combined with Chlorpromazine.
Diazepam	Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Levomilnacipran.
Oxazepam	Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Levomilnacipran.
Flurazepam	Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Levomilnacipran.
Clorazepate	Clorazepate The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Levomilnacipran.
Lorazepam	Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Levomilnacipran.
Carmustine	Carmustine Carmustine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Amantadine	Amantadine The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Levomilnacipran.
Codeine	Codeine The risk or severity of serotonin syndrome can be increased when Levomilnacipran is combined with Codeine.
Meprobamate	Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Levomilnacipran.
Chlordiazepoxide	Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Levomilnacipran.
Bromocriptine	Bromocriptine The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Bromocriptine.
Metaproterenol	Metaproterenol Levomilnacipran may increase the tachycardic activities of Orciprenaline.
Tranylcypromine	Tranylcypromine Tranylcypromine may increase the serotonergic activities of Levomilnacipran.
Phenelzine	Phenelzine Phenelzine may increase the serotonergic activities of Levomilnacipran.
Procarbazine	Procarbazine Procarbazine may increase the serotonergic activities of Levomilnacipran.
Ergoloid Mesylates	Ergoloid Mesylates The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Levomilnacipran.
Tetracycline	Tetracycline Tetracycline may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Minocycline	Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.
Prochlorperazine	Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levomilnacipran.
Thioridazine	Thioridazine The metabolism of Levomilnacipran can be decreased when combined with Thioridazine.
Trifluoperazine	Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levomilnacipran.
Bleomycin	Bleomycin Bleomycin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Dapsone	Dapsone The metabolism of Levomilnacipran can be decreased when combined with Dapsone.
Sulfadiazine	Sulfadiazine The metabolism of Levomilnacipran can be decreased when combined with Sulfadiazine.
Oxycodone	Oxycodone The risk or severity of serotonin syndrome can be increased when Oxycodone is combined with Levomilnacipran.
Methadone	Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Levomilnacipran.
Oxybutynin	Oxybutynin The metabolism of Levomilnacipran can be decreased when combined with Oxybutynin.
Benztropine	Benztropine Benzatropine may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.
Maprotiline	Maprotiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Levomilnacipran.
Ibuprofen	Ibuprofen The risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Levomilnacipran.
Trihexyphenidyl	Trihexyphenidyl Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
Orphenadrine	Orphenadrine Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Perphenazine	Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Levomilnacipran.
Azathioprine	Azathioprine Azathioprine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Fluphenazine	Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Levomilnacipran.
Phentermine	Phentermine The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Levomilnacipran.
Methylphenidate	Methylphenidate Methylphenidate may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Amoxapine	Amoxapine The metabolism of Levomilnacipran can be decreased when combined with Amoxapine.
Sulfasalazine	Sulfasalazine The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Sulfasalazine.
Hydrocortisone	Hydrocortisone The metabolism of Levomilnacipran can be increased when combined with Hydrocortisone.
Doxorubicin	Doxorubicin The metabolism of Levomilnacipran can be decreased when combined with Doxorubicin.
Phenazopyridine	Phenazopyridine Phenazopyridine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Carbamazepine	Carbamazepine The metabolism of Levomilnacipran can be increased when combined with Carbamazepine.
Molindone	Molindone The risk or severity of adverse effects can be increased when Molindone is combined with Levomilnacipran.
Methyldopa	Methyldopa Methyldopa may increase the tachycardic activities of Levomilnacipran.
Clonidine	Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Levomilnacipran.
Hydralazine	Hydralazine Hydralazine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Cimetidine	Cimetidine The metabolism of Levomilnacipran can be decreased when combined with Cimetidine.
Gentamicin Injection	Gentamicin Injection Gentamicin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Warfarin	Warfarin The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Warfarin.
Clonazepam	Clonazepam The risk or severity of adverse effects can be increased when Clonazepam is combined with Levomilnacipran.
Loperamide	Loperamide The metabolism of Levomilnacipran can be decreased when combined with Loperamide.
Promethazine	Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Levomilnacipran.
Meclofenamate	Meclofenamate The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Meclofenamic acid.
Nitrofurantoin	Nitrofurantoin Nitrofurantoin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Griseofulvin	Griseofulvin The metabolism of Levomilnacipran can be increased when combined with Griseofulvin.
Digoxin	Digoxin The risk or severity of hypotension can be increased when Levomilnacipran is combined with Digoxin.
Loxapine	Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Levomilnacipran.
Chloroquine	Chloroquine The metabolism of Levomilnacipran can be decreased when combined with Chloroquine.
Quinine	Quinine The metabolism of Levomilnacipran can be decreased when combined with Quinine.
Ethosuximide	Ethosuximide The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Ethosuximide.
Calcitriol	Calcitriol The metabolism of Levomilnacipran can be increased when combined with Calcitriol.
Triamterene	Triamterene Triamterene may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Sulfinpyrazone	Sulfinpyrazone The metabolism of Levomilnacipran can be increased when combined with Sulfinpyrazone.
Chlorothiazide	Chlorothiazide The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Chlorothiazide.
Chlorthalidone	Chlorthalidone The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Chlorthalidone.
Metolazone	Metolazone The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Metolazone.
Isosorbide	Isosorbide Isosorbide may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.
Secobarbital	Secobarbital The metabolism of Levomilnacipran can be increased when combined with Secobarbital.
Desipramine	Desipramine The metabolism of Levomilnacipran can be decreased when combined with Desipramine.
Amitriptyline	Amitriptyline The metabolism of Levomilnacipran can be decreased when combined with Amitriptyline.
Imipramine	Imipramine The metabolism of Levomilnacipran can be decreased when combined with Imipramine.
Probenecid	Probenecid The metabolism of Levomilnacipran can be increased when combined with Probenecid.
Quinidine	Quinidine The metabolism of Levomilnacipran can be decreased when combined with Quinidine.
Procainamide	Procainamide The metabolism of Procainamide can be decreased when combined with Levomilnacipran.
Isoniazid	Isoniazid The risk or severity of serotonin syndrome can be increased when Isoniazid is combined with Levomilnacipran.
Pyrazinamide	Pyrazinamide Pyrazinamide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Rifampin	Rifampin The metabolism of Levomilnacipran can be increased when combined with Rifampicin.
Disopyramide	Disopyramide Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.
Valproic Acid	Valproic Acid The risk or severity of adverse effects can be increased when Valproic acid is combined with Levomilnacipran.
Tamoxifen	Tamoxifen The metabolism of Levomilnacipran can be increased when combined with Tamoxifen.
Butabarbital	Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Levomilnacipran.
Levothyroxine	Levothyroxine The metabolism of Levothyroxine can be decreased when combined with Levomilnacipran.
Liothyronine	Liothyronine Liothyronine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Methimazole	Methimazole The metabolism of Levomilnacipran can be decreased when combined with Methimazole.
Propylthiouracil	Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Levomilnacipran.
Chlorpropamide	Chlorpropamide The risk or severity of hypoglycemia can be increased when Chlorpropamide is combined with Levomilnacipran.
Tolbutamide	Tolbutamide The metabolism of Levomilnacipran can be decreased when combined with Tolbutamide.
Tolazamide	Tolazamide The risk or severity of hypoglycemia can be increased when Tolazamide is combined with Levomilnacipran.
Dextromethorphan	Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Levomilnacipran.
Cyclobenzaprine	Cyclobenzaprine The risk or severity of CNS depression can be increased when Levomilnacipran is combined with Cyclobenzaprine.
Niacin	Niacin The metabolism of Levomilnacipran can be decreased when combined with Niacin.
Baclofen	Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Levomilnacipran.
Doxylamine	Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.
Cyproheptadine	Cyproheptadine The therapeutic efficacy of Levomilnacipran can be decreased when used in combination with Cyproheptadine.
Clemastine	Clemastine The risk or severity of adverse effects can be increased when Clemastine is combined with Levomilnacipran.
Chlorpheniramine	Chlorpheniramine The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Levomilnacipran.
Brompheniramine	Brompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levomilnacipran.
Meclizine	Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Levomilnacipran.
Ethambutol	Ethambutol Ethambutol may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Methyclothiazide	Methyclothiazide The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Methyclothiazide.
Hydrochlorothiazide	Hydrochlorothiazide The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Hydrochlorothiazide.
Dantrolene	Dantrolene The risk or severity of adverse effects can be increased when Dantrolene is combined with Levomilnacipran.
Chlorzoxazone	Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Levomilnacipran.
Carisoprodol	Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Levomilnacipran.
Methocarbamol	Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Levomilnacipran.
Pyridoxine	Pyridoxine Pyridoxine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Folic Acid	Folic Acid Folic acid may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Propranolol (Cardiovascular)	Propranolol (Cardiovascular) The serum concentration of Propranolol can be increased when it is combined with Levomilnacipran.
Pseudoephedrine	Pseudoephedrine The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Levomilnacipran.
Nortriptyline	Nortriptyline The metabolism of Levomilnacipran can be decreased when combined with Nortriptyline.
Spironolactone	Spironolactone The metabolism of Levomilnacipran can be decreased when combined with Spironolactone.
Amphotericin B Injection	Amphotericin B Injection Amphotericin B may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Phytonadione	Phytonadione Phylloquinone may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Amikacin Injection	Amikacin Injection Amikacin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Nadolol	Nadolol The serum concentration of Nadolol can be increased when it is combined with Levomilnacipran.
Butorphanol Injection	Butorphanol Injection The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Levomilnacipran.
Nalbuphine Injection	Nalbuphine Injection The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Levomilnacipran.
Allopurinol	Allopurinol Allopurinol may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Trimethobenzamide	Trimethobenzamide The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Levomilnacipran.
Flavoxate	Flavoxate Flavoxate may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.
Fluorouracil Injection	Fluorouracil Injection The metabolism of Levomilnacipran can be decreased when combined with Fluorouracil.
Colchicine	Colchicine The metabolism of Levomilnacipran can be increased when combined with Colchicine.
Cefaclor	Cefaclor Cefaclor may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Cefadroxil	Cefadroxil Cefadroxil may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Cefazolin Injection	Cefazolin Injection Cefazolin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Cephalexin	Cephalexin Cephalexin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Cefoxitin Injection	Cefoxitin Injection Cefoxitin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Dacarbazine	Dacarbazine Dacarbazine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Acetazolamide	Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Levomilnacipran.
Cefotaxime Injection	Cefotaxime Injection Cefotaxime may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Calcitonin Salmon Injection	Calcitonin Salmon Injection Salmon calcitonin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Ketoconazole	Ketoconazole The metabolism of Levomilnacipran can be decreased when combined with Ketoconazole.
Pyrantel	Pyrantel The risk or severity of adverse effects can be increased when Pyrantel is combined with Levomilnacipran.
Dipyridamole	Dipyridamole The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Dipyridamole.
Isoxsuprine	Isoxsuprine Levomilnacipran may increase the tachycardic activities of Isoxsuprine.
Vinblastine	Vinblastine The metabolism of Levomilnacipran can be increased when combined with Vinblastine.
Ethacrynic Acid	Ethacrynic Acid Etacrynic acid may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Colistimethate Injection	Colistimethate Injection Colistimethate may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Metoprolol	Metoprolol The metabolism of Metoprolol can be decreased when combined with Levomilnacipran.
Hydroxyzine	Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.
Thiothixene	Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Levomilnacipran.
Aspirin	Aspirin Levomilnacipran may increase the antiplatelet activities of Acetylsalicylic acid.
Salsalate	Salsalate The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Salsalate.
Alprazolam	Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Levomilnacipran.
Temazepam	Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Levomilnacipran.
Triazolam	Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Levomilnacipran.
Dicyclomine	Dicyclomine Dicyclomine may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.
Hyoscyamine	Hyoscyamine Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Propantheline	Propantheline Propantheline may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.
Trimethoprim	Trimethoprim The metabolism of Levomilnacipran can be decreased when combined with Trimethoprim.
Diltiazem	Diltiazem The metabolism of Levomilnacipran can be decreased when combined with Diltiazem.
Nifedipine	Nifedipine The metabolism of Levomilnacipran can be increased when combined with Nifedipine.
Timolol	Timolol The serum concentration of Timolol can be increased when it is combined with Levomilnacipran.
Verapamil	Verapamil The metabolism of Levomilnacipran can be decreased when combined with Verapamil.
Atenolol	Atenolol The serum concentration of Atenolol can be increased when it is combined with Levomilnacipran.
Pindolol	Pindolol The risk or severity of adverse effects can be increased when Pindolol is combined with Levomilnacipran.
Cisplatin Injection	Cisplatin Injection Levomilnacipran may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Diflunisal	Diflunisal The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Diflunisal.
Piroxicam	Piroxicam The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Piroxicam.
Bumetanide	Bumetanide Bumetanide may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.
Etoposide	Etoposide The metabolism of Levomilnacipran can be increased when combined with Etoposide.
Glyburide	Glyburide The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Glyburide.
Glipizide	Glipizide The risk or severity of hypoglycemia can be increased when Glipizide is combined with Levomilnacipran.
Indapamide	Indapamide The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Indapamide.
Amoxicillin	Amoxicillin Amoxicillin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Dicloxacillin	Dicloxacillin The metabolism of Levomilnacipran can be increased when combined with Dicloxacillin.
Nafcillin Injection	Nafcillin Injection The metabolism of Levomilnacipran can be increased when combined with Nafcillin.
Oxacillin Injection	Oxacillin Injection Oxacillin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Pentoxifylline	Pentoxifylline Levomilnacipran may increase the antiplatelet activities of Pentoxifylline.
Pentamidine Injection	Pentamidine Injection Pentamidine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Ceftriaxone Injection	Ceftriaxone Injection Ceftriaxone may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Labetalol	Labetalol The serum concentration of Labetalol can be increased when it is combined with Levomilnacipran.
Auranofin	Auranofin Auranofin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Leuprolide Injection	Leuprolide Injection Leuprolide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Gemfibrozil	Gemfibrozil The metabolism of Levomilnacipran can be decreased when combined with Gemfibrozil.
Guanabenz	Guanabenz Levomilnacipran may increase the tachycardic activities of Guanabenz.
Dipivefrin Ophthalmic	Dipivefrin Ophthalmic Adefovir dipivoxil may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Ceftazidime Injection	Ceftazidime Injection Ceftazidime may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Ketoprofen	Ketoprofen The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Ketoprofen.
Cefotetan Injection	Cefotetan Injection Cefotetan may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Pimozide	Pimozide The risk or severity of QTc prolongation can be increased when Levomilnacipran is combined with Pimozide.
Flurbiprofen	Flurbiprofen The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Flurbiprofen.
Amiodarone	Amiodarone The metabolism of Amiodarone can be decreased when combined with Levomilnacipran.
Aztreonam Injection	Aztreonam Injection Aztreonam may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Buspirone	Buspirone The risk or severity of serotonin syndrome can be increased when Buspirone is combined with Levomilnacipran.
Lovastatin	Lovastatin The metabolism of Levomilnacipran can be decreased when combined with Lovastatin.
Ciprofloxacin	Ciprofloxacin Ciprofloxacin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Mesalamine	Mesalamine The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Mesalazine.
Diclofenac	Diclofenac The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Diclofenac.
Fluoxetine	Fluoxetine The serum concentration of Levomilnacipran can be increased when it is combined with Fluoxetine.
Clozapine	Clozapine The metabolism of Levomilnacipran can be decreased when combined with Clozapine.
Estazolam	Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Levomilnacipran.
Idarubicin	Idarubicin The metabolism of Levomilnacipran can be decreased when combined with Idarubicin.
Didanosine	Didanosine Didanosine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Pentostatin Injection	Pentostatin Injection Pentostatin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Clarithromycin	Clarithromycin The metabolism of Levomilnacipran can be decreased when combined with Clarithromycin.
Etodolac	Etodolac The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Etodolac.
Felodipine	Felodipine The metabolism of Felodipine can be decreased when combined with Levomilnacipran.
Fosinopril	Fosinopril Fosinopril may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Nabumetone	Nabumetone The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Nabumetone.
Simvastatin	Simvastatin The metabolism of Levomilnacipran can be decreased when combined with Simvastatin.
Itraconazole	Itraconazole The metabolism of Levomilnacipran can be decreased when combined with Itraconazole.
Lisinopril	Lisinopril Lisinopril may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Oxaprozin	Oxaprozin The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Oxaprozin.
Rifabutin	Rifabutin The metabolism of Levomilnacipran can be increased when combined with Rifabutin.
Sotalol	Sotalol The metabolism of Sotalol can be decreased when combined with Levomilnacipran.
Bisoprolol	Bisoprolol The serum concentration of Bisoprolol can be increased when it is combined with Levomilnacipran.
Zolpidem	Zolpidem Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Doxazosin	Doxazosin The metabolism of Levomilnacipran can be decreased when combined with Doxazosin.
Isradipine	Isradipine Isradipine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Omeprazole	Omeprazole The metabolism of Levomilnacipran can be increased when combined with Omeprazole.
Cisapride	Cisapride The metabolism of Cisapride can be decreased when combined with Levomilnacipran.
Gabapentin	Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Levomilnacipran.
Fluvastatin	Fluvastatin The metabolism of Levomilnacipran can be decreased when combined with Fluvastatin.
Venlafaxine	Venlafaxine The metabolism of Levomilnacipran can be decreased when combined with Venlafaxine.
Fluvoxamine	Fluvoxamine The metabolism of Levomilnacipran can be decreased when combined with Fluvoxamine.
Nefazodone	Nefazodone The metabolism of Levomilnacipran can be decreased when combined with Nefazodone.
Lamotrigine	Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Levomilnacipran.
Losartan	Losartan The metabolism of Levomilnacipran can be decreased when combined with Losartan.
Valacyclovir	Valacyclovir Valaciclovir may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Tramadol	Tramadol The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Levomilnacipran.
Vinorelbine Injection	Vinorelbine Injection The metabolism of Levomilnacipran can be decreased when combined with Vinorelbine.
Carboplatin Injection	Carboplatin Injection Carboplatin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Lansoprazole	Lansoprazole The metabolism of Levomilnacipran can be increased when combined with Lansoprazole.
Ifosfamide Injection	Ifosfamide Injection The metabolism of Levomilnacipran can be increased when combined with Ifosfamide.
Nicardipine	Nicardipine The metabolism of Levomilnacipran can be decreased when combined with Nicardipine.
Bupropion	Bupropion The metabolism of Levomilnacipran can be decreased when combined with Bupropion.
Ticlopidine	Ticlopidine Levomilnacipran may increase the antiplatelet activities of Ticlopidine.
Saquinavir	Saquinavir The metabolism of Saquinavir can be decreased when combined with Levomilnacipran.
Metformin	Metformin The risk or severity of hypoglycemia can be increased when Metformin is combined with Levomilnacipran.
Dalteparin Injection	Dalteparin Injection The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Dalteparin.
Nisoldipine	Nisoldipine Nisoldipine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Lamivudine	Lamivudine Lamivudine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Riluzole	Riluzole The risk or severity of adverse effects can be increased when Riluzole is combined with Levomilnacipran.
Acarbose	Acarbose The risk or severity of hypoglycemia can be increased when Acarbose is combined with Levomilnacipran.
Glimepiride	Glimepiride The risk or severity of hypoglycemia can be increased when Glimepiride is combined with Levomilnacipran.
Anastrozole	Anastrozole The metabolism of Levomilnacipran can be decreased when combined with Anastrozole.
Gemcitabine Injection	Gemcitabine Injection Gemcitabine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Ritonavir	Ritonavir The serum concentration of Levomilnacipran can be increased when it is combined with Ritonavir.
Cidofovir Injection	Cidofovir Injection Cidofovir may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Meropenem Injection	Meropenem Injection Meropenem may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Clomipramine	Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Levomilnacipran.
Zafirlukast	Zafirlukast The metabolism of Levomilnacipran can be decreased when combined with Zafirlukast.
Fosfomycin	Fosfomycin Fosfomycin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Mirtazapine	Mirtazapine Levomilnacipran may increase the serotonergic activities of Mirtazapine.
Topiramate	Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Levomilnacipran.
Insulin Lispro Injection	Insulin Lispro Injection The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Levomilnacipran.
Pramipexole	Pramipexole Levomilnacipran may increase the sedative activities of Pramipexole.
Donepezil	Donepezil The risk or severity of adverse effects can be increased when Donepezil is combined with Levomilnacipran.
Nelfinavir	Nelfinavir The metabolism of Levomilnacipran can be decreased when combined with Nelfinavir.
Loratadine	Loratadine The metabolism of Levomilnacipran can be decreased when combined with Loratadine.
Carvedilol	Carvedilol The serum concentration of Carvedilol can be increased when it is combined with Levomilnacipran.
Nilutamide	Nilutamide The metabolism of Levomilnacipran can be decreased when combined with Nilutamide.
Flutamide	Flutamide Flutamide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Selegiline	Selegiline Selegiline may increase the serotonergic activities of Levomilnacipran.
Bicalutamide	Bicalutamide The metabolism of Levomilnacipran can be decreased when combined with Bicalutamide.
Sertraline	Sertraline The risk or severity of adverse effects can be increased when Sertraline is combined with Levomilnacipran.
Propafenone	Propafenone The metabolism of Levomilnacipran can be decreased when combined with Propafenone.
Raloxifene	Raloxifene The metabolism of Levomilnacipran can be decreased when combined with Raloxifene.
Irbesartan	Irbesartan The metabolism of Levomilnacipran can be decreased when combined with Irbesartan.
Tamsulosin	Tamsulosin Tamsulosin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Ropinirole	Ropinirole Levomilnacipran may increase the sedative activities of Ropinirole.
Quetiapine	Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Levomilnacipran.
Cefepime Injection	Cefepime Injection Cefepime may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Cefprozil	Cefprozil Cefprozil may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Cefpodoxime	Cefpodoxime Cefpodoxime may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Cetirizine	Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Levomilnacipran.
Paroxetine	Paroxetine The metabolism of Levomilnacipran can be decreased when combined with Paroxetine.
Tolcapone	Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Levomilnacipran.
Citalopram	Citalopram The risk or severity of adverse effects can be increased when Citalopram is combined with Levomilnacipran.
Capecitabine	Capecitabine Capecitabine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Efavirenz	Efavirenz The metabolism of Levomilnacipran can be decreased when combined with Efavirenz.
Abacavir	Abacavir Abacavir may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Sildenafil	Sildenafil The metabolism of Levomilnacipran can be decreased when combined with Sildenafil.
Pioglitazone	Pioglitazone The metabolism of Levomilnacipran can be decreased when combined with Pioglitazone.
Celecoxib	Celecoxib The risk or severity of bleeding can be increased when Celecoxib is combined with Levomilnacipran.
Rosiglitazone	Rosiglitazone The metabolism of Levomilnacipran can be decreased when combined with Rosiglitazone.
Tolterodine	Tolterodine Tolterodine may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.
Thalidomide	Thalidomide Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Oseltamivir	Oseltamivir Oseltamivir may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Balsalazide	Balsalazide The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Balsalazide.
Nateglinide	Nateglinide The risk or severity of hypoglycemia can be increased when Nateglinide is combined with Levomilnacipran.
Galantamine	Galantamine The metabolism of Levomilnacipran can be decreased when combined with Galantamine.
Levetiracetam	Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Levomilnacipran.
Rabeprazole	Rabeprazole The metabolism of Levomilnacipran can be decreased when combined with Rabeprazole.
Terbinafine	Terbinafine The metabolism of Levomilnacipran can be decreased when combined with Terbinafine.